European equities traded in the US as American depositary receipts were lower late Thursday morning, declining 0.4% to 1,444.8 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and semiconductor company Sequans Communications (SQNS), which rose 2.9% and 2.5% respectively. They were followed by furniture maker Natuzzi (NTZ) and internet advertising firm Criteo (CRTO), which were up 1.5% and 1.4% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and health technology conglomerate Royal Philips (PHG), which fell 6.2% and 2.4% respectively. They were followed by oil and gas company Eni (E) and accommodations booking company trivago (TRVG), which were down 1.8% and 1.3% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Autolus Therapeutics (AUTL), which climbed 18.4% and 2% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and biopharmaceutical company Verona Pharma (VRNA), which increased 1% and 0.8% respectively.
The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which dropped 4.1% and 3.2% respectively. They were followed by alcoholic beverage company Diageo (DEO) and biotech firm Trinity Biotech (TRIB), which lost 2.7% and 2.5% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.